Inhibiting the formation of new blood vessels is a common strategy for treating a range of conditions such as cancer, inflammatory diseases, and age-related macular degeneration.
Unfortunately, drug inefficiency, resistance, and relapse have limited the success of this approach. Now new research publishing online December 12 in the Cell Press journal Cell Metabolism reveals that targeting the metabolism of blood vessels may be a way around these shortcomings.
“Our findings reveal a new strategy to block blood vessel growth in various pathological conditions by depriving them of energy and building blocks necessary for growth,” says senior author Dr. Peter Carmeliet of the University of Leuven and the Vesalius Research Center, VIB in Belgium.
While current strategies to thwart pathological blood vessel formation focus primarily on inhibiting vascular endothelial growth factor (VEGF), this latest research centers around blocking glycolysis, the process that endothelial cells rely on for generating most of the energy they need to multiply and migrate. Endothelial cells form the inner lining of a blood vessel and provide a barrier between the vessel wall and blood.
Dr. Carmeliet and his team previously found that the glycolytic activator PFKFB3 promotes blood vessel formation by stimulating glycolysis in endothelial cells. In their new work, the investigators discovered that blocking PFKFB3 with a small molecule called 3PO reduced blood vessel sprouting by inhibiting the proliferation and movement of endothelial cells.
3PO also amplified the effects of VEGF blockade. And although 3PO reduced glycolysis only partially and transiently, this sufficed to decrease pathological blood vessel formation in both ocular and inflammatory laboratory models. “As many cells in the body need glycolysis for growth and survival, the partial and transient reduction of glycolysis might limit the side effects and toxicity of this therapy in the clinic,” Dr. Carmeliet notes.
The findings could lead to new treatments that block the excessive blood vessel growth that supports cancer spread, causes blindness, and fuels inflammatory diseases such as psoriasis and inflammatory bowel disease.
The Latest on: Pathological blood vessel formation
[google_news title=”” keyword=”pathological blood vessel formation” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pathological blood vessel formation
- Medivir´s MIV-711 gets US FDA rare paediatric disease designation and orphan drug designation to treat Legg-Calvé-Perthes diseaseon April 25, 2024 at 8:30 pm
Stockholm, Sweden Friday, April 26, 2024, 09:00 Hrs [IST] ...
- FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Diseaseon April 24, 2024 at 8:34 pm
Cathepsin K inhibition protects the damaged bone by reducing bone resorption and promoting bone formation, thereby addressing the key mechanisms causing pathological changes in LCPD, with potential to ...
- LSU Health Shreveport Researcher Elected as a 2023 Fellow of American Association for the Advancement of Scienceon April 22, 2024 at 1:05 pm
Christopher G. Kevil, PhD, Vice Chancellor for Research at LSU Health Shreveport (LSUHS), has been named a Fellow of the American Association for the Advancement of Science ...
- LSU Health Shreveport researcher elected 2023 Fellow of American Association for the Advancement of Scienceon April 19, 2024 at 4:46 pm
LSU Health Shreveport’s Christopher G. Kevil, PhD, LSU Health vice chancellor for research, has been given a prestigious award from the American Association for The Advancement of Science.
- Myopia Treatment - Unlock the Potential of Your Eyeson April 19, 2024 at 5:26 am
Myopia, aka near-sightedness, is an eye condition where you can clearly see objects close to you but struggle to see objects at a greater distance.
- What Is Placenta Extracts And Common Side Effectson April 13, 2024 at 2:28 pm
What is it and what is it used forPlacenta Extracts is a topical medication used to treat wounds that are not healing or healing very slowly. It promotes wound healing with minimal scars. It has ...
- Case 11-2024: An 82-Year-Old Woman with Falls and Cognitive Declineon April 10, 2024 at 2:34 pm
An 82-year-old woman was admitted because of difficulty walking, falls, and cognitive decline. Light touch of the right hand, right knee, and both feet caused pain. A diagnosis was made.
via Bing News